Repare Therapeutics RPTX 深 沪
等待开盘 09-04 09:30:00 美东时间
1.72
+0.020
+1.18%
华盛通- 最 高1.73
- 今 开1.71
- 成交量 9.11万股
- 最 低 1.70
- 昨 收 1.70
- 总市值 7388.98万
- 52周最高 4.0695
- 市盈率 静 --
- 换手率 0.21%
- 52周最低 0.89
- 委 比 -53.61%
- 总股本 4295.92万
- 历史最高 46.44
- 量 比 0.81
- 振 幅 1.76%
- 历史最低 0.89
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics reported Q2 and H1 2025 financial results, highlighting a net loss of $17.6 million for Q2 and $34.8 million for H1, compared to $27.7 million and $58.2 million in 2024. R&D expenses decreased by $10.3 million and $23.0 million, while G&A expenses increased slightly. The company strengthened its team and pipeline, with plans to initiate a Phase 2b trial for RPT904 in food allergy later this year and report topline results from J...
08-07 12:00
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
reAlpha Tech Corp. Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
reAlpha Tech Corp. announced the purchase and sale of 14,285,718 shares of its common stock at $0.35 per share in a registered direct offering under Nasdaq rules. Concurrently, the company will issue unregistered warrants for up to 14,285,718 shares with an exercise price of $0.35 per share, exercisable immediately and expiring in five years. The offering is expected to close on July 22, 2025, subject to customary closing conditions. H.C. Wainwri...
07-21 20:30
Repare Therapeutics shares are trading higher after the company entered a licensing agreement with Debiopharm for Lunresertib.
Repare Therapeutics shares are trading higher after the company entered a licen...
07-16 04:11
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
RAPT Therapeutics announced the addition of Scott Braunstein, M.D., to its Audit Committee and Ashley Dombkowski, Ph.D., to its Nominating and Corporate Governance Committee. Both bring extensive industry experience. RAPT’s lead product, RPT904, a novel monoclonal antibody targeting free IgE, is completing Phase 2 trials in chronic spontaneous urticaria and asthma, with plans for a Phase 2 study in food allergy later this year. The company aims t...
06-23 12:00
Repare Therapeutics Updates Severance Benefits for Executives
Repare Therapeutics ( ($RPTX) ) has issued an announcement. On June 13, 2025, R...
06-21 04:42
12款小分子新药化学结构首次公开
转自：中国医药报 在前不久美国化学会（ACS）举行的2025春季会议上，12款已进入或即将进入临床试验的小分子药物的化学结构首次公开亮相，这些潜在的新药适应证...
06-19 08:18
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Autolus Therapeutics presents updated FELIX study data on obe-cel for adult r/r B-ALL, showing a median response duration of 42.6 months, with over half of patients in remission at 24 months. Notably, 38% of ongoing responders did not require subsequent therapy by month 33. Results suggest obe-cel may offer durable remission without further treatment for some patients.
06-12 06:00
Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
Radiopharm Theranostics announced the U.S. FDA granted Fast Track Designation for RAD101 to distinguish recurrent disease from treatment effect in brain metastases. RAD101 targets fatty acid synthase (FASN), overexpressed in many solid tumors, including cerebral metastases. The Phase 2 clinical trial evaluates RAD101's diagnostic performance in patients with confirmed recurrent brain metastases, aiming to improve diagnostic precision and clinical...
06-11 12:00
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on treating inflammatory and immunological diseases, announced that its management team will participate in two investor conferences in June: a fireside chat at Goldman Sachs' Global Healthcare Conference on June 10 and investor one-on-one meetings at the UBS Spring Biotech Conference on June 24. Visit their website for details on accessing the Goldman Sachs event.
06-04 20:05
